Eli Lilly and Company (NYSE:LLY) Shares Sold by Nicolet Bankshares Inc.

Nicolet Bankshares Inc. cut its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 2.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,590 shares of the company’s stock after selling 44 shares during the period. Nicolet Bankshares Inc.’s holdings in Eli Lilly and Company were worth $854,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cassia Capital Partners LLC grew its position in shares of Eli Lilly and Company by 1.8% in the third quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock valued at $511,000 after purchasing an additional 17 shares during the last quarter. Walkner Condon Financial Advisors LLC lifted its stake in Eli Lilly and Company by 2.8% during the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after purchasing an additional 17 shares during the last quarter. Patton Albertson Miller Group LLC lifted its stake in Eli Lilly and Company by 2.8% during the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after purchasing an additional 17 shares during the last quarter. Valley Wealth Managers Inc. lifted its stake in shares of Eli Lilly and Company by 1.3% in the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after acquiring an additional 17 shares during the last quarter. Finally, Lathrop Investment Management Corp lifted its stake in shares of Eli Lilly and Company by 1.2% in the 3rd quarter. Lathrop Investment Management Corp now owns 1,476 shares of the company’s stock valued at $793,000 after acquiring an additional 18 shares during the last quarter. 81.38% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $630.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 1st. UBS Group reiterated a “buy” rating and set a $710.00 price target (up from $612.00) on shares of Eli Lilly and Company in a report on Friday, October 20th. Barclays increased their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Wednesday, November 8th. Finally, TheStreet lowered Eli Lilly and Company from a “b” rating to a “c+” rating in a research report on Monday, December 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $621.81.

Check Out Our Latest Report on LLY

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 14,388 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $630.28, for a total value of $9,068,468.64. Following the sale, the insider now owns 99,754,422 shares in the company, valued at $62,873,217,098.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders have sold 195,055 shares of company stock worth $125,254,657. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Down 1.1 %

Shares of NYSE LLY traded down $8.03 on Monday, reaching $732.13. 2,066,299 shares of the company’s stock traded hands, compared to its average volume of 3,398,719. Eli Lilly and Company has a 12 month low of $309.20 and a 12 month high of $745.70. The business’s 50 day simple moving average is $620.02 and its two-hundred day simple moving average is $581.92. The company has a market cap of $695.02 billion, a price-to-earnings ratio of 127.61, a price-to-earnings-growth ratio of 2.08 and a beta of 0.32. The company has a quick ratio of 0.82, a current ratio of 1.05 and a debt-to-equity ratio of 1.59.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 50.78%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter last year, the firm earned $2.09 earnings per share. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. As a group, equities research analysts forecast that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Thursday, February 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.20 annualized dividend and a yield of 0.71%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 77.93%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.